GlassScriptPhysician profile
Andrew Chacko
NPI 1457092942
$4,466.11
in general payments reported to CMS, 2019-2025
11 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $599 · 2023: $241 · 2024: $1,869 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,965 · Food and Beverage: $700 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,965.00 |
| Food and Beverage | $700.28 |
| Education | $201.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,828.65 | 2022-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $1,528.83 | 2022-2024 | Imfinzi |
| Abbvie INC. | $449.63 | 2022-2024 | Venclexta, Avycaz |
| Merck Sharp & Dohme LLC | $143.06 | 2022-2024 | Keytruda |
| Lilly USA, LLC | $131.57 | 2024 | Verzenio |
| Biohaven Pharmaceutical Holding Company LTD. | $124.93 | 2022 | |
| Sobi, INC | $89.45 | 2024 | |
| Novartis Pharmaceuticals Corporation | $79.68 | 2025 | |
| Seagen INC. | $52.80 | 2022-2023 | Adcetris |
| Janssen Biotech, INC. | $23.36 | 2024 | Rybrevant |
| Csl Behring | $14.15 | 2023 | Kcentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Chacko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.